TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›MXCT›Financials
Annual statements · SEC XBRL · FY2019 – FY2025

MAXCYTE, INC. (MXCT) financials

Income statement

MAXCYTE, INC. (MXCT) income statement, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$13.3M$15.5M$21.6M$28.7M$19.5M$22.2M$21.0M
Revenue growth—16.6%39.6%33.3%-32.2%13.9%-5.7%
Gross profit$19.1M$23.4M$30.2M$39.2M$36.5M$31.5M$26.8M
Gross margin144.2%151.5%140.2%136.2%187.4%141.9%127.9%
Operating income-$12.4M-$11.1M-$18.2M-$27.4M-$48.3M-$51.2M-$51.9M
Operating margin-93.7%-71.6%-84.3%-95.2%-247.7%-230.5%-247.6%
Net income-$12.9M-$11.8M-$19.1M-$23.6M-$37.9M-$41.1M-$44.6M
Net margin-97.3%-76.5%-88.5%-82.0%-194.5%-184.8%-213.0%
EPS (diluted)-$0.23-$0.17-$0.21-$0.23-$0.37-$0.39-$0.42

Cash flow

MAXCYTE, INC. (MXCT) cash flow, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$8.80M-$8.78M-$10.7M-$14.8M-$21.7M-$27.6M-$34.4M
Capital expenditures$1.27M$2.07M$3.83M$18.5M$3.70M$1.65M$1.77M
Free cash flow-$10.1M-$10.9M-$14.5M-$33.3M-$25.4M-$29.3M-$36.2M

Balance sheet

MAXCYTE, INC. (MXCT) balance sheet, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$15.2M$18.8M$47.8M$11.1M$46.5M$27.9M$20.1M
Total assets—$51.8M$284M$287M$268M$239M$203M
Total liabilities—$18.6M$21.2M$32.7M$36.1M$33.2M$31.0M
Shareholders' equity$13.6M$33.2M$263M$254M$232M$206M$171M
Retained earnings—-$95.2M-$114M-$138M-$176M-$217M-$261M
Shares (wtd avg diluted)56.4M69.5M90.6M102M103M105M106M

Every figure is extracted from MAXCYTE, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is MAXCYTE, INC.'s annual revenue?
MAXCYTE, INC. (MXCT) reported $21.0M of revenue for fiscal year 2025 — down 5.7% from $22.2M in FY2024, per its annual report filed with the SEC.
Is MAXCYTE, INC. profitable?
Not in FY2025 — MXCT reported a net loss of $44.6M, per SEC filings.
What is MAXCYTE, INC.'s free cash flow?
-$36.2M in FY2025 (operating cash flow -$34.4M minus $1.77M of capital expenditures), from the SEC cash-flow statement.
Does MXCT pay a dividend?
MAXCYTE, INC. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full MXCT analysis — verdict, score & filings →Is MXCT a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.